Agammaglobulinemia: comorbidities and long-term therapeutic risks

References

• Abolhassani H, Mirminachi B, Vitali M, et al. Clinical features and mutation analysis of Iranian patients with congenital agammaglobulinemia. J Clin Immunol. 2014;34:S385–S86.
   Google Scholar
• Abolhassani H, Vitali M, Lougaris V, et al. Cohort of Iranian patients with congenital agammaglobulinemia: mutation analysis and novel gene defects. Expert Rev Clin Immunol. 2016 Apr 2;12(4):479–486.
   Google Scholar
• Aghamohammadi A, Fiorini M, Moin M, et al. Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. Int Arch Allergy Imm. 2006;141(4):408–414.
   Google Scholar
• Aghamohammadi A, Plebani A, Lougaris V, et al. Predominantly antibody deficiencies. In: Rezaei N, Aghamohammadi A, Notarangelo LD editors. Primary immunodeficiency diseases: definition, diagnosis, and management. Berlin: Springer; 2017. p. 183–244.
   Google Scholar
• Gathmann B, Grimbacher B, Beauté J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009 accepted Mar 30;157(Suppl 1):3–11.
   Google Scholar
• Aghamohammadi A, Mohammadinejad P, Abolhassani H, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014 May;34(4):478–490.
   Google Scholar
• Rezaei N, Aghamohammadi A, Moin M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian primary immunodeficiency registry. J Clin Immunol. 2006 Nov;26(6):519–532.
   Google Scholar
• Aghamohammadi A, Abolhassani H, Latif A, et al. Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients. Expert Rev Clin Immunol. 2014 Oct;10(10):1405–1417.
   Google Scholar
• Moin M, Aghamohammadi A, Farhoudi A, et al. X-linked agammaglobulinemia: a survey of 33 Iranian patients. Immunol Invest. 2004;33(1):81–93.
   Google Scholar
• Aghamohammadi A, Farhoudi A, Moin M, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immun. 2005 Jul;12(7):825–832.
   Google Scholar
• Abolhassani H, Parvaneh N, Rezaei N, et al. Genetic defects in B-cell development and their clinical consequences. J Invest Allerg Clin. 2014;24(1):6–22.
   Google Scholar
• Suri D, Rawat A, Singh S. X-linked agammaglobulinemia. Indian J Pediatr. 2016 Apr;83(4):331–337.
   Google Scholar
• Mohammadinejad P, Pourhamdi S, Abolhassani H, et al. Primary antibody deficiency in a tertiary referral hospital: a 30-year experiment. J Investig Allergol Clin Immunol. 2015;25(6):416–425.
   Google Scholar
• Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine. 2006 Jul;85(4):193–202.
   Google Scholar
• Bearden D, Collett M, Quan PL, et al. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016 Nov – Dec;4(6):1059–1065.
   Google Scholar
• Shaghaghi M, Shahmahmoodi S, Abolhassani H, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995–2014. Emerg Infect Dis. 2016 Oct;22(10):1712–1719.
   Google Scholar
• Aghamohammadi A, Cheraghi T, Rezaei N, et al. Neutropenia associated with X-linked agammaglobulinemia in an Iranian referral center. Iran J Allergy Asthm. 2009 Mar;8(1):43–47.
   Google Scholar
• Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. Eur J Pediatr. 2011 May 05; 170(6):693–702.
   Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012 Dec;32(6):1180–1192.
   Google Scholar
• Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011 May;7(3):301–316.
   Google Scholar
• Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004 Mar 08;40(2):113–118.
   Google Scholar
• Winkelstein JA, Conley ME, James C, et al. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine. 2008 Sep;87(5):253–258.
   Google Scholar
• Rhim JW, Kim KH, Kim DS, et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci. 2012 Jul;27(7):788–793.
   Google Scholar
• Marie I, Cherin P, Michallet M, et al. [Management of adverse effects related to human immunoglobulin therapy: recommendations for clinical practice]. La Revue De Medecine Interne. 2017 May;38(5):312–319.
   Google Scholar
• Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013 Aug;73(12):1307–1319.
   Google Scholar
• Verma N, Thaventhiran A, Gathmann B, et al. Therapeutic management of primary immunodeficiency in older patients. Drugs Aging. 2013 Jul;30(7):503–512.
   Google Scholar
• Azizi G, Ahmadi M, Abolhassani H, et al. Autoimmunity in primary antibody deficiencies. Int Arch Allergy Immunol. 2016;171(3–4):180–193.
   Google Scholar
• Winkelstein JA, Conley ME, James C, et al. Status of adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine. 2008;87(5):253–258.
   Google Scholar
• Ng YS, Wardemann H, Chelnis J, et al. Bruton’s tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004 Oct 04;200(7):927–934.
   Google Scholar
• Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, et al. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 2014 Aug;34(6):627–632.
   Google Scholar
• Barmettler S, Otani IM, Minhas J, et al. Gastrointestinal manifestations in X-linked agammaglobulinemia. J Clin Immunol. 2017 Feb 24.
   Google Scholar
• Corneth OB, Klein Wolterink RG, Hendriks RW. BTK signaling in B cell differentiation and autoimmunity. Curr Top Microbiol Immunol. 2016;393:67–105.
   Google Scholar
• Norman P. Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2016 Aug;25(8):891–899.
   Google Scholar
• Kanegane H, Taneichi H, Nomura K, et al. Severe neutropenia in Japanese patients with x-linked agammaglobulinemia. J Clin Immunol. 2005 Sep;25(5):491–495.
   Google Scholar
• Azizi G, Abolhassani H, Asgardoon M, et al. Managing patients with side effects and adverse events to immunoglobulin therapy. Expert Rev Clin Pharmacol. 2016 [cited 2016 Jan 02];9(1):91–102.
   Google Scholar
• Kersseboom R, Middendorp S, Dingjan GM, et al. Bruton’s tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J Exp Med. 2003 Jul 07;198(1):91–98.
   Google Scholar
• Althubiti M, Rada M, Samuel J, et al. BTK modulates p53 activity to enhance apoptotic and senescent responses. Cancer Res. 2016 Sep 15;76(18):5405–5414.
   Google Scholar
• Hoshino A, Okuno Y, Migita M, et al. X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia. J Clin Immunol. 2015 Feb;35(2):108–111.
   Google Scholar
• Feldhahn N, Rio P, Soh BN, et al. Deficiency of Bruton’s tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci USA. 2005 Sep 13;102(37):13266–13271.
   Google Scholar
• Gayko U, Fung M, Clow F, et al. Development of the Bruton’s tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci. 2015;1358:82–94.
   Google Scholar
• van der Meer JW, Weening RS, Schellekens PT, et al. Colorectal cancer in patients with X-linked agammaglobulinaemia. Lancet (London, England). 1993 Jun 05;341(8858):1439–1440.
   Google Scholar
• Desar IM, Van Deuren M, Sprong T, et al. Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia. Clin Exp Immunol. 2009 Jun;156(3):434–439.
   Google Scholar
• Echave-Sustaeta JM, Villena V, Verdugo M, et al. X-linked agammaglobulinaemia and squamous lung cancer. Eur Respir J. 2001 Mar;17(3):570–572.
   Google Scholar
• Costa-Carvalho BT, Wandalsen GF, Pulici G, et al. Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol (Madr). 2011 May–Jun;39(3):128–132.
   Google Scholar
• Dosanjh A. Chronic pediatric pulmonary disease and primary humoral antibody based immune disease. Respir Med. 2011 Apr;105(4):511–514.
   Google Scholar
• Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011 Jun;31(3):315–322.
   Google Scholar
• Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clinical Immunology (Orlando, Fla). 2010 Oct;137(1):21–30.
   Google Scholar
• Chen Y, Stirling RG, Paul E, et al. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol. 2011 Jun;127(6):1414–1417.
   Google Scholar
• Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001 Aug 07;135(3):165–174.
   Google Scholar
• Chan HY, Yang YH, Yu HH, et al. Clinical characteristics and outcomes of primary antibody deficiency: a 20-year follow-up study. J Formos Med Assoc = Taiwan Yi Zhi. 2014 Jun;113(6):340–348.
   Google Scholar
• Cordey S, Schibler M, L’Huillier AG, et al. Comparative analysis of viral shedding in pediatric and adult subjects with central nervous system-associated enterovirus infections from 2013 to 2015 in Switzerland. J Clin Virol. 2017;89:22–29.
   Google Scholar
• Shahmahmoodi S, Mamishi S, Aghamohammadi A, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995–2008. Emerg Infect Dis. 2010;16(7):1133–1136.
   Google Scholar
• Shaghaghi M, Shahmahmoodi S, Abolhassani H, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995–2014. Emerg Infect Dis. 2016 Oct;22(10):1712–1719.
   Google Scholar
• Fiore L, Plebani A, Buttinelli G, et al. Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clinical Immunology (Orlando, Fla). 2004 Apr;111(1):98–102.
   Google Scholar
• Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. THE characterization of the protein fractions of human plasma. J Clin Invest. 1944 Jul;23(4):417–432.
   Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722.
   Google Scholar
• Barandun S, Kistler P, Jeunet F, et al. Intravenous administration of human γ‐globulin. Vox Sang. 1962;7(2):157–174.
   Google Scholar
• Abolhassani H, Asgardoon MH, Rezaei N, et al. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol. 2015;11(11):1229–1243.
   Google Scholar
• Sriaroon P, Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2015 Nov;35(4):713–730.
   Google Scholar
• Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf. 2010 Nov;9(6):971–979.
   Google Scholar
• Friman V, Winqvist O, Blimark C, et al. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121–132.
   Google Scholar
• Duraisingham SS, Buckland M, Dempster J, et al. Primary vs. Secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS ONE. 2014 Jun 27; 9(6):e100324.
   Google Scholar
• Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the primary immunodeficiency committee of the American Academy of allergy asthma and immunology. Clinical Immunology (Orlando, Fla). 2010 May;135(2):255–263.
   Google Scholar
• Spadaro G, Vultaggio A, Alberto Bosi A, et al. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. Int Immunopharmacol. 2017 Jan 07;44:38–42.
   Google Scholar
• Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017 Mar;139(3S):S1–S46.
   Google Scholar
• Koterba AP, Stein MR. Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy. Allergy Asthma Clin Immunol. 2015;11(1):63.
   Google Scholar
• Patel NC, Gallagher JL, Ochs HD, et al. Subcutaneous immunoglobulin replacement therapy with hizentra(R) is safe and effective in children less than 5 years of age. J Clin Immunol. 2015 Aug;35(6):558–565.
   Google Scholar
• Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012 Dec;32(6):1153–1164.
   Google Scholar
• Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553–567.
   Google Scholar
• Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004 Oct;114(4):936–942.
   Google Scholar
• Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders–a prospective study. J Neurol. 2003 Jul;250(7):818–821.
   Google Scholar
• Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of allergy, asthma and immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl):S525–53.
   Google Scholar
• Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139–145.
   Google Scholar
• Park DH, Kang GB, Kang DE, et al. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations. Biologicals:Jl Int Assoc Biol Standardization. 2017;45:1–8.
   Google Scholar
• Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med. 2010 Sep;122(5):176–184.
   Google Scholar
• Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection Ige Antibodies Iga New England Journal Medicine. 1986 Feb 27;314(9):560–564.
   Google Scholar
• Schweisfurth H, Sopivnik I, Moog R. [Transfusion-related acute lung injury (TRALI)]. Pneumologie (Stuttgart, Germany). 2014 Sep;68(9):599–603.
   Google Scholar
• Kim J, Na S. Transfusion-related acute lung injury; clinical perspectives. Korean J Anesthesiol. 2015 Mar 30 68(2):101–105.
   Google Scholar
• Reesink HW, Lee J, Keller A, et al. Measures to prevent transfusion-related acute lung injury (TRALI). Vox Sang. 2012 Oct;103(3):231–259.
   Google Scholar
• Benson AB, Moss M, Silliman CC. Transfusion-Related Acute Lung Injury (TRALI): a clinical review with emphasis on the critically Ill. Br J Haematol. 2009 Aug 05;147(4):431–443.
   Google Scholar
• Gorlinger K, Saner FH. Prophylactic plasma and platelet transfusion in the critically Ill patient: just useless and expensive or even harmful? BMC Anesthesiol. 2015 Jun;09(15):86.
   Google Scholar
• Rogers TS, Fung MK, Harm SK. Recent advances in preventing adverse reactions to transfusion. F1000Research. 2015 Dec 17;4. pii: F1000 Faculty Rev-1469.
   Google Scholar
• Eder AF, Dy BA, O’Neill EM. Predicted effect of selectively testing female donors for HLA antibodies to mitigate transfusion-related acute lung injury risk from apheresis platelets. Transfusion. 2016 Jun;56(6 Pt 2):1608–1615.
   Google Scholar
• Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of postoperative transfusion-related acute lung injury. Anesthesiology. 2015 Jan;122(1):12–20.
   Google Scholar
• Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38(4):275–284.
   Google Scholar
• Moulis G, Sailler L, Sommet A, et al. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study. Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):314–319.
   Google Scholar
• Clark SL, Rabinstein AA. Safety of intravenous immunoglobulin and plasma exchange in critically ill patients. Neurol Res. 2015 Jul;37(7):593–598.
   Google Scholar
• Clark SL, Rabinstein AA. Safety of intravenous immunoglobulin and plasma exchange in critically ill patients. Neurol Res. 2015 Jun 02;37(7):593–598.
   Google Scholar
• Rajabally YA, Kearney DA. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci. 2011 Sep 15;308(1–2):124–127.
   Google Scholar
• Ramirez E, Romero-Garrido JA, Lopez-Granados E, et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res. 2014 Jun;133(6):1045–1051.
   Google Scholar
• Haplea S, Farrar J, Gibson G, et al. Thromboembolic events associated with intravenous immunoglobulin therapy. Neurology. LIPPINCOTT-RAVEN PUBL 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106. 1997;48(3):1090–1090.
   Google Scholar
• Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013 Jul;39(5):559–566.
   Google Scholar
• Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang. 2013 Jul;105(1):54–64.
   Google Scholar
• Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol. 2004 Oct;83(10):661–665.
   Google Scholar
• Hansen RJ, Balthasar JP. Mechanisms of IVIG action in immune thrombocytopenic purpura. Clin Lab. 2004;50(3–4):133–140.
   Google Scholar
• Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008 Aug;48(8):1598–1601.
   Google Scholar
• Berg R, Shebl A, Kimber MC, et al. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Transfusion. 2015 Jul;55(Suppl 2):S36–46.
   Google Scholar
• Bharath V, Eckert K, Kang M, et al. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Transfusion. 2015 Nov;55(11):2597–2605.
   Google Scholar
• Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016 Jan;15(1):71–81.
   Google Scholar
• Alerhand S, Cassella C, Koyfman A. Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review. Pediatr Emerg Care. 2016 Jul;32(7):472–476.
   Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013 Jul;27(3):171–178.
   Google Scholar
• Roberts PL, Dunkerley C, Walker C. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation. Biologicals:Jl Int Assoc Biol Standardization. 2012 Sep;40(5):345–352.
   Google Scholar
• Boschetti N, Stucki M, Spath PJ, et al. Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol. 2005 Dec;29(3):333–344.
   Google Scholar
• Sandomenico A, Severino V, Chambery A, et al. A comparative structural and bioanalytical study of IVIG clinical lots. Mol Biotechnol. 2013 Jul;54(3):983–995.
   Google Scholar
• Bichuetti-Silva DC, Furlan FP, Nobre FA, et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol. 2014 Dec;23(2):442–446.
   Google Scholar